Browse News
Filter News
Found 485,773 articles
-
Eli Lilly has signed a collaboration deal with CureVac that could total up to $1.8B.
-
Biotech stocks are generally viewed as highly volatile. Of course, along with volatility comes the possibility for huge upside rewards.
-
Two weeks after securing more than $46M in financing, Visterra struck a deal worth up to $1B with startup Vir Biotech.
-
Alnylam and startup Vir Biotech inked a deal worth up to $1B for the development and marketing of RNAi therapies aimed at treating infectious diseases including HBV.
-
Sachem Head Capital Management is pushing for that company to break up into small entities in order to increase shareholder value.
-
The round was led by new investors as well as existing investors.
-
The good news led Ignyta's stock to jump about five percent before settling down.
-
Arthrex will build a new state-of-the-art surgical device and implant manufacturing facility in Anderson County, S.C.
-
Reckitt to Break Up Company in Restructuring
10/18/2017
The company has decided to split its business into two units - consumer healthcare and home and hygiene products -
Vertex has done everything an investor could ask for in 2017, including double its market cap to almost $40B.
-
Askbio and Columbus Venture Partners Launch Gene Therapy Company Viralgen
10/18/2017
Asklepios BioPharma announced the formation of Viralgen, a gene therapy joint venture with Columbus Venture Partners.
-
3 More Moderna R&D Execs Quietly Step Down
10/18/2017
So this year, Moderna has lost the head of its cancer division, its top lawyer, and its chief business officer. -
Former Eli Lilly Exec Emerges as the Front-Runner for Top HHS Job
10/18/2017
Alex Azar worked at the Department of Health and Human Services under President George W. Bush before joining drugmaker Eli Lilly.
-
Pernix Therapeutics Announces Planned Departure of Chief Financial Officer
10/18/2017
Graham Miao, Ph.D., President and Chief CFO, will leave the Company at the end of the year in order to pursue other opportunities.
-
Innovus Pharma Receives Approval From Health Canada for Vesele as a Natural Health Product
10/18/2017
Innovus Pharma announced that it has received approval from Health Canada to market its best-selling, clinically proven Vesele product as a Natural Health Product ("NHP") to help improve nitric oxide production involved in symptoms of sexual dysfunction.
-
The FDA has previously set February 8, 2018 as the Prescription Drug User Fee Act ("PDUFA") goal date.
-
Photocure ASA: FDA Grants Priority Review for Cysview Supplemental New Drug Application (sNDA)
10/18/2017
With the FDA granting a priority review, a decision is expected in the first half of 2018.
-
FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD)
10/18/2017
The NDA submission triggers a $15 million milestone payment, payable to FibroGen by AstraZeneca.
-
FDA Accepts Regulatory Submission for AstraZeneca's LYNPARZA (Olaparib) in Metastatic Breast Cancer and Grants Priority Review
10/18/2017
LYNPARZA has the potential to offer a new treatment option for patients with germline BRCA-mutated, HER2-negative metastatic breast cancer.
-
Novartis Drug Revolade Shows Long-Term Disease Control for Chronic/Persistent Immune Thrombocytopenia (ITP)
10/18/2017
The long term study results were published online in Blood.